Billing Pros on Prior Authorization Burden and Beyond

Why It Matters

Reduced reimbursements and added administrative overhead threaten lab profitability and could limit patient access to essential diagnostics. Legislative and payer reforms are critical to sustain the financial health of the pathology sector.

Key Takeaways

• Medicare Advantage plans downcode STI tests to panel codes, cutting lab revenue
• Labs face costly appeals to recover underpayments from downcoding
• CMS efficiency adjustment reduces pathology payments despite increased documentation workload
• Congressional Rep. Raul Ruiz pushes legislation to mitigate efficiency‑adjustment cuts
• Technical component volumes rise while professional component volumes decline

Pulse Analysis

The laboratory billing landscape is increasingly complex, with prior‑authorization requirements and denials adding layers of administrative strain. Beyond the routine hurdles, Medicare Advantage insurers have begun downcoding high‑volume infectious‑disease tests—such as chlamydia, gonorrhea, and Trichomonas—into bundled panel codes. This practice trims reimbursement rates, forcing labs to launch appeals that consume resources and inflate operational costs. The shift reflects a broader payer strategy to control expenses, but it also raises compliance concerns when coding standards diverge from traditional Medicare guidelines.

Compounding the payer‑driven challenges, the Centers for Medicare & Medicaid Services (CMS) introduced an efficiency adjustment that assumes laboratories can deliver the same services with fewer resources. Critics argue the model overlooks the growing complexity of pathology documentation and the time required for case sign‑outs, effectively penalizing labs that have actually increased workload. The adjustment has sparked pushback from industry leaders and lawmakers alike, with Representative Raul Ruiz spearheading legislative efforts to recalibrate the formula and protect pathology revenues.

In response, labs and billing firms are exploring mitigation tactics such as gold‑carding programs that streamline prior‑authorization workflows and shifting service mixes toward technical components (TC) that remain more financially viable. The trend toward higher TC volumes, contrasted with declining professional component (PC) reimbursements, signals a strategic realignment to preserve margins. As advocacy intensifies and regulatory scrutiny grows, the sector’s ability to adapt will determine whether it can sustain essential diagnostic services without compromising financial stability.